Treatment resistant schizophrenia (TRS), the lack of response to at least two antipsychotics administered at adequate dose and duration, epitomizes in psychiatry one of the most difficult-to-treat pathologies, epidemiologically relevant (affecting one-third of schizophrenia patients) and with severe consequences for the patients in terms of overall functioning. After 50 years, only one drug is approved for TRS: clozapine. Furthermore, a few patients do not respond even to clozapine and are indicated as clozapine-resistant patients.
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia / de Bartolomeis, Andrea; Ciccarelli, Mariateresa; Vellucci, Licia; Fornaro, Michele; Iasevoli, Felice; Barone, Annarita. - In: EXPERT OPINION ON PHARMACOTHERAPY. - ISSN 1465-6566. - 23:18(2022), pp. 2035-2052. [10.1080/14656566.2022.2145884]
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia
de Bartolomeis, Andrea
;Ciccarelli, Mariateresa;Vellucci, Licia;Fornaro, Michele;Iasevoli, Felice;Barone, Annarita
2022
Abstract
Treatment resistant schizophrenia (TRS), the lack of response to at least two antipsychotics administered at adequate dose and duration, epitomizes in psychiatry one of the most difficult-to-treat pathologies, epidemiologically relevant (affecting one-third of schizophrenia patients) and with severe consequences for the patients in terms of overall functioning. After 50 years, only one drug is approved for TRS: clozapine. Furthermore, a few patients do not respond even to clozapine and are indicated as clozapine-resistant patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
